ClinicalTrials.gg
CompletedNCT05607680Updated Nov 12, 2024

A Study of IBI362 in Participants With Obesity or Overweight

A Phase 3 interventional study of Placebo and IBI362 in Obesity Or Overweight, sponsored by Innovent Biologics (Suzhou) Co. Ltd.. Completed at 23 sites in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-11-12.

Sponsored by Innovent Biologics (Suzhou) Co. Ltd. (part of Innovent Biologics, Inc.) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
610
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 22 studies testing mazdutide in Obesity — 11 open to participants now, 14 under way, 4 of them phase 3. mazdutide · Obesity.

Enrollment
3rd of 22
610 · median 187
Started
2022
with 1 other
Phase 3
6 of 22
3 open now
Registered
4th of 22
by date
Lead sponsor
12 of 22
Innovent Biologics (Suzhou) Co. Ltd.

Among the 22 studies testing mazdutide in Obesity, this one is the 3rd largest by enrollment, is one of 2 that started in 2022, is one of 6 in phase 3, and was the 4th registered.

Obesity

11,543 studies on the registry are indexed under Obesity; 2,047 are open to participants now.

Browse Obesity studies →

Open to participants now

11 of the 22 studies testing mazdutide in Obesity are open now, in 3 countries. Recruiting first, the newest first:

6 more — sign in →

By country, each count listing its studies:

All 11 open studies →

Where they have run

About mazdutide

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 1,342 Obesity studies recruiting now, 377 (28%) set no upper age limit and 861 (64%) stop at 75 or younger; 168 take children under 18; 489 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 22 studies testing mazdutide in Obesity, or all of them as a file.
02

Study summary

This is a multicenter, randomized, double-blind, placebo-controlled Phase III clinical study evaluating the efficacy and safety of IBI362 in overweight or obese subjects. Subjects will be randomly assigned to IBI362 low-dose, high-dose and placebo groups. The entire trial cycle includes a 2-week screening period, a 48-week double-blind treatment period, and a 12-week drug withdrawal follow-up period after the end of treatment.

03

Conditions studied

  • Obesity Or Overweight
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • (BMI) ≥28 kilograms per square meter (kg/m²), or ≥24 kg/m² and with at least one of the following comorbidities: prediabetes, hypertension, dyslipidemia, fatty liver, weight bearing joint pain, obesity-related dyspnea or obstructive sleep apnea.

Exclusion criteria

Exclusion Criteria:

  • ≥ 6. 5% at screening or previous diagnosis of type 1 or type 2 diabetes;
  • Weight change > 5.0% after diet and exercise control for at least 12 weeks before screening;
  • Have used or are currently using weight loss drugs within 3 months before screening;
  • History of pancreatitis;
  • Family or personal history of thyroid C-cell carcinoma or multiple endocrine neoplasia (MEN) 2A or 2B;
  • History of moderate to severe depression or severe mental illness;
  • Any lifetime history of a suicide attempt
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
610 participants (actual)

Study arms

  • Placebo comparator
    Placebo

    Placebo,SC,once a week for 48 weeks

    Drug: Placebo

  • Experimental
    IBI362 4 mg

    2 mg,SC,once a week for 4 weeks 4 mg,SC,once a week for 44 weeks

    Drug: IBI362

  • Experimental
    IBI362 6 mg

    2 mg,SC,once a week for 4 weeks 4 mg,SC,once a week for 4 weeks 6 mg,SC,once a week for 40 weeks

    Drug: IBI362

Interventions

  • DrugPlacebo

    Placebo administered subcutaneously (SC) once a week.

  • DrugIBI362

    IBI362 administered subcutaneously (SC) once a week.

06

What researchers measure

Primary outcomes

  1. Percent Change from Baseline in Body Weight

    Time frame: Baseline, Week 32

  2. Percentage of Participants who Achieve ≥5% Body Weight Reduction

    Time frame: Week 32

Secondary outcomes

  1. Percentage of Participants who Achieve ≥10%Body Weight Reduction

    Time frame: Week 32,Week 48

  2. Percentage of Participants who Achieve ≥15% Body Weight Reduction

    Time frame: Week 32,Week 48

  3. Change from Baseline in Waist Circumference

    Time frame: Baseline, Week 32,Week 48

  4. Percent Change from Baseline in Body Weight

    Time frame: Baseline, Week 48

  5. Percentage of Participants who Achieve ≥5% Body Weight Reduction

    Time frame: Week 48

  6. Percentage of Participants who Achieve ≥20% Body Weight Reduction

    Time frame: Week 32, Week 48

  7. Change from Baseline in Neck Circumference

    Time frame: Baseline, Week 32, Week 48

  8. Change from Baseline in Hip Circumference

    Time frame: Baseline, Week 32, Week 48

  9. Change from Baseline in Body Weight

    Time frame: Baseline, Week 32, Week 48

  10. Percent Change from Baseline in Body Weight

    Time frame: Baseline, Week 60

  11. Change from Baseline in Body Mass Index (BMI)

    Time frame: Baseline, Week 32, Week 48

  12. Percentage of Participants with BMI < 24 kg/m2

    Time frame: Week 32, Week 48

  13. Change from Baseline in Systolic Blood Pressure

    Time frame: Baseline, Week 32, Week 48

  14. Change from Baseline in Diastolic Blood Pressure

    Time frame: Baseline, Week 32, Week 48

  15. Change from Baseline in Triglyceride

    Time frame: Baseline, Week 32,Week 48

  16. Change from Baseline in Total Cholesterol

    Time frame: Baseline, Week 32, Week 48

  17. Change from Baseline in Low-density Lipoprotein Cholesterol

    Time frame: Baseline, Week 32, Week 48

  18. Change from Baseline in High-density Lipoprotein Cholesterol

    Time frame: Baseline, Week 32, Week 48

  19. Change from Baseline in Serum Uric Acid

    Time frame: Baseline, Week 32, Week 48

  20. Change from Baseline in Alanine Aminotransferase

    Time frame: Baseline, Week 32, Week 48

  21. Change from Baseline in Aspartate Aminotransferase

    Time frame: Baseline, Week 32, Week 48

  22. Change from Baseline in Glycated Hemoglobin A1c (HbA1c)

    Time frame: Baseline, Week 32, Week 48

  23. Change from Baseline in Fasting Plasma Glucose

    Time frame: Baseline, Week 32, Week 48

  24. Change from Baseline in Fasting Insulin

    Time frame: Baseline, Week 32, Week 48

  25. Change from Baseline in Fasting C-peptide

    Time frame: Baseline, Week 32, Week 48

  26. Change from Baseline in Homeostatic Model Assessment of Insulin Resistance-Insulin Resistance Index (HOMA2-IR)

    Time frame: Baseline, Week 32, Week 48

  27. Change from Baseline in IWQoL-Lite-CT Questionnaire Scores

    Time frame: Baseline, Week 32, Week 48

  28. Change from Baseline in SF-36v2 Questionnaire Scores

    Time frame: Baseline, Week 32, Week 48

07

Study locations

23 sites
  • Xuancheng People's Hospital
    Xuancheng, Anhui, China
  • People's Hospital of Peking University
    Beijing, Beijing 100044, China
  • Hebei Petro China Central Hospital
    Langfang, Hebei, China
  • Luoyang Third People's Hospital
    Luoyang, Henan, China
  • The First Affiliated Hospital of Henan University of Science and Technology
    Luoyang, Henan, China
  • The First Affiliated Hospital of Nanyang Medical University
    Nanyang, Henan, China
  • The Third Affiliated Hospital of Xinxiang Medical University
    Xinxiang, Henan, China
  • The First People's Hospital Of Kunshan
    Kunshan, Jiangsu, China
  • Nanjing Drum Tower Hospital
    Nanjing, Jiangsu, China
  • Affiliated Hospital Of Nantong University
    Nantong, Jiangsu, China
  • Suzhou Municipal Hospital
    Suzhou, Jiangsu, China
  • Pingxiang People's Hospital
    Pingxiang, Jiangxi, China
  • China-Japan Union Hospital of Jilin University
    Changchun, Jilin, China
  • Shenyang Fifth People's Hospital
    Shenyang, Liaoning, China
  • Jinan Central Hospital
    Ji'nan, Shandong, China
  • Shandong Provincial Third Hospital
    Ji'nan, Shandong, China
  • Qilu Hospital Of Shandong University (Qingdao)
    Qingdao, Shandong, China
  • Tai'an Central Hospital
    Tai'an, Shandong, China
  • Zibo Municipal Hospital
    Zibo, Shandong, China
  • Shanxi Bethune Hospital
    Taiyuan, Shanxi, China
  • Yan'an University Xianyang Hospital
    Xianyang, Shanxi, China
  • Huzhou Central Hospital
    Huzhou, Zhejiang, China
  • Lishui Central Hospital
    Lishui, Zhejiang, China
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2022 to primary completion in Aug 2023, 9 months.

Of 199 industry-sponsored phase 3 interventional studies under Obesity, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 27. This study's 9 months is below that.

Counting every sponsor, half of 262 studies reached it within 24 months; a quarter within 18 and three quarters within 34.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 23, 2022
First posted
Nov 7, 2022
StartActual
Nov 14, 2022
Primary completionActual
Aug 21, 2023
CompletionActual
Apr 16, 2024
Last update
Nov 12, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 12, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05607680
Responsible party
Sponsor
First posted
Nov 7, 2022
Start date
Nov 14, 2022
Primary completion
Aug 21, 2023
Completion
Apr 16, 2024
Last update
Nov 12, 2024

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Mazdutide

Start the discussion